Integrated Safety Analysis of Vedolizumab for the Treatment of Ulcerative Colitis or Crohn's Disease

被引：0
|
作者：
Colombel, Jean-Frederic
Sands, Bruce E.
Feagan, Brian G.
Loftus, Edward V.
Sankoh, Serap
Fox, Irving
Parikh, Asit
Milch, Catherine
机构：
来源：
GASTROENTEROLOGY | 2013年 / 144卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：S113 / S113
页数：1
相关论文
共 50 条
  • [41] Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease
    Rosario, M.
    Dirks, N. L.
    Gastonguay, M. R.
    Fasanmade, A. A.
    Wyant, T.
    Parikh, A.
    Sandborn, W. J.
    Feagan, B. G.
    Reinisch, W.
    Fox, I.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2015, 42 (02) : 188 - 202
  • [42] The role of vedolizumab in patients with moderate-to-severe Crohn's disease and ulcerative colitis
    Shahidi, Neal
    Bressler, Brian
    Panaccione, Remo
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2016, 9 (03) : 330 - 338
  • [43] Hospitalizations and Treatment Discontinuation among Patients with Ulcerative Colitis and Crohn's Disease Treated with Vedolizumab Compared with Infliximab
    Khalid, Javaria Mona
    Raluy-Callado, Mireia
    Alam, Naufi L.
    Wang, Rosa
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 : S317 - S317
  • [44] Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease
    Tilg, Herbert
    Kaser, Arthur
    CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2010, 11 (11) : 1295 - 1304
  • [45] Clinical decision support tool for vedolizumab can predict treatment persistence in Crohn's disease but not in ulcerative colitis
    Ocepek, A.
    Molinari, N.
    Macek, P.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1847 - I1847
  • [46] The Safety Profile of Vedolizumab in Ulcerative Colitis and Crohn's Disease: 4 Years of Global Post-marketing Data
    Cohen, Russell D.
    Bhayat, Fatima
    Blake, Aimee
    Travis, Simon
    JOURNAL OF CROHNS & COLITIS, 2020, 14 (02): : 192 - 204
  • [47] Quantification of the Hypothetical Risk of Progressive Multifocal Leukoencephalopathy with Vedolizumab Treatment in Patients with Ulcerative Colitis and Crohn's Disease
    Xu, Jing
    Card, Timothy
    Shick, Jesse
    Palo, William
    Liang, Huifang
    Bhayat, Fatima
    INFLAMMATORY BOWEL DISEASES, 2017, 23 : S54 - S54
  • [48] Chronic inflammatory intestinal diseases:Crohn's disease and ulcerative colitis.: Part 2:: Imaging of ulcerative colitis,treatment of Crohn's disease and ulcerative colitis
    Feuerbach, S
    Scholmerich, J
    RADIOLOGE, 2000, 40 (04): : 415 - 428
  • [49] Vedolizumab for the treatment of ulcerative colitis
    Stallmach, Andreas
    Schmidt, Carsten
    Teich, Niels
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2016, 10 (02) : 165 - 175
  • [50] Vedolizumab for the treatment of ulcerative colitis
    Rietdijk, Svend T.
    D'Haens, Geert R.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2014, 7 (04) : 423 - 430
12345